Streetbeat News

Revenues

PKX

POSCO HOLDINGS reported a decline in Q3 2024 revenue and profit compared to the previous year. Revenue decreased from KRW9.68T to KRW9.48T, and profit fell from KRW0.50T to KRW0.27T. These figures are based on preliminary data and may change after the independent auditors' review.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 2:09 pm

HUM

Humana Inc (NYSE:HUM) reported strong Q3 earnings, beating expectations with an EPS of $4.16 and revenues of $29.30 billion, driven by Medicare growth. The company raised its 2024 profit outlook and expects continued growth in Medicare Advantage membership.

Portfolio Pulse from Vandana Singh

October 30, 2024 | 2:05 pm

DHI

KBH

PHM

SPY

TOL

The USA Pending Home Sales for September increased by 7.4%, significantly surpassing the estimated 1.9% and the previous month's 0.6%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 2:04 pm

CBRE

CBRE Group (NYSE:CBRE) has outperformed the market over the past 5 years, achieving an average annual return of 18.91%. A $100 investment in CBRE 5 years ago would now be worth $240.72, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 2:00 pm

LNG

Cheniere Energy (NYSE:LNG) has significantly outperformed the market over the past 20 years, with an annualized return of 14.1%. A $1000 investment in LNG 20 years ago would now be worth $13,741, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 2:00 pm

SPY

A White House official highlighted the need to lower key costs while acknowledging progress in the economy. The official expects lower payroll numbers this week due to hurricanes and strikes but emphasized the resilience of the labor market.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:48 pm

GRMN

Garmin Ltd reported strong Q3 2024 earnings with a 24% revenue growth to $1.59 billion, surpassing analyst expectations. The company's EPS also exceeded estimates, leading to a stock price increase. Garmin raised its FY24 outlook, anticipating higher revenue and EPS.

Portfolio Pulse from Anusuya Lahiri

October 30, 2024 | 1:46 pm

ABBV

AbbVie has reduced its 2024 U.S. sales forecast for Humira by $400 million to $7.4 billion, reflecting a shift in volume to other products like Skyrizi and Rinvoq.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:38 pm

ABBV

AbbVie has updated its sales expectations for two of its key drugs, Skyrizi and Rinvoq. The company now anticipates global sales of $11.5 billion for Skyrizi and $5.8 billion for Rinvoq this year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:36 pm

CSCO

WYY

WidePoint's IT Authorities has secured over $1.7 million in contracts for Cisco and managed IT services, with $1.4 million awarded in Q3. Clients include various sectors such as beverage distribution and sports marketing.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:30 pm